All In Biotech

Drug Trial Radar · NCT06786624

Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jan 22, 2025

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Jan 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Conditions

  • Major Depressive Disorder

Interventions

  • OsavampatorDrug

    Osavampator tablets

  • PlaceboDrug

    Matching placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56Time frame: Baseline, Day 56

Locations

30 sites in 4 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Little Rock, Arkansas · Recruiting

  • Neurocrine Clinical Site

    Garden Grove, California · Withdrawn

  • Neurocrine Clinical Site

    Orange, California · Withdrawn

  • Neurocrine Clinical Site

    Pico Rivera, California · Recruiting

  • Neurocrine Clinical Site

    San Diego, California · Recruiting

  • Neurocrine Clinical Site

    Upland, California · Withdrawn

  • Neurocrine Clinical Site

    Hollywood, Florida · Recruiting

  • Neurocrine Clinical Site

    Maitland, Florida · Recruiting

  • Neurocrine Clinical Site

    Boston, Massachusetts · Recruiting

  • Neurocrine Clinical Site

    Watertown, Massachusetts · Suspended

  • Neurocrine Clinical Site

    Mount Kisco, New York · Recruiting

  • Neurocrine Clinical Site

    Avon Lake, Ohio · Recruiting

  • Neurocrine Clinical Site

    Westlake, Ohio · Withdrawn

  • Neurocrine Clinical Site

    Dallas, Texas · Withdrawn

  • Neurocrine Clinical Site

    Houston, Texas · Recruiting

  • Neurocrine Clinical Site

    Richmond, Texas · Withdrawn

  • Neurocrine Clinical Site

    The Woodlands, Texas · Suspended

  • Neurocrine Clinical Site

    Everett, Washington · Recruiting

  • Neurocrine Clinical Site

    Zagreb, Croatia · Active not recruiting

  • Neurocrine Clinical Site

    Zagreb, Croatia · Active not recruiting

  • Neurocrine Clinical Site

    Pilsen, Czechia · Active not recruiting

  • Neurocrine Clinical Site

    Prague, Czechia · Active not recruiting

  • Neurocrine Clinical Site

    Prague, Czechia · Active not recruiting

  • Neurocrine Clinical Site

    Prague, Czechia · Active not recruiting

  • Neurocrine Clinical Site

    Prague, Czechia · Active not recruiting

  • Neurocrine Clinical Site

    Bełchatów, Poland · Active not recruiting

  • Neurocrine Clinical Site

    Bialystok, Poland · Active not recruiting

  • Neurocrine Clinical Site

    Gdansk, Poland · Active not recruiting

  • Neurocrine Clinical Site

    Grudziądz, Poland · Active not recruiting

  • Neurocrine Clinical Site

    Katowice, Poland · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.